Author

Radka Macova

Institutions: Slovak Academy of Sciences, Cancer Research Institute of the Slovak Academy of Sciences, Biomedical Research Center of the Slovak Academy of Sciences, Comenius University Bratislava

Observed institutions: Slovak Academy of Sciences, Cancer Research Institute of the Slovak Academy of Sciences, Biomedical Research Center of the Slovak Academy of Sciences, Comenius University Bratislava

ORCID: 0000-0002-3033-4648

Observed ORCID: 0000-0002-3033-4648

OpenAlex ID: A5092537745

Novel Strategies Enhancing Bioavailability and Therapeutical Potential of Silibinin for Treatment of Liver Disorders

2024 · Michal Selc, Radka Macova, et al. · Drug Design Development and Therapy · 26

Effects of different-sized silver nanoparticles on morphological and functional alterations in lung cancer and non-cancer lung cells

2023 · Kristina Jakic, Michal Selc, et al. · Neoplasma · 3

Nanoparticle-boosted silymarin: Are we overlooking taxifolin and other key components?

2025 · Michal Selc, Radka Macova, et al. · Frontiers in Plant Science · 2

Targeting TIMP-1 in hepatic fibrosis with milk thistle flavonolignans: mechanistic evidence and prospects for gold nanoparticle delivery

2026 · Radka Macova, Andrea Babelova, et al. · American Journal of Physiology-Cell Physiology

A splice odyssey: periostin’s journey through the sea of crabs

2026 · Radka Macova, Michal Selc, et al. · Neoplasma

Isosilybin B: a potential novel therapeutic agent with hepatoprotective, anticancer and antifibrotic properties

2025 · Michal Selc, Kristina Jakic, et al. · Discover Oncology

Works count: 6

Citation count: 31

H-index: 2

I10-index: 1